ARTL News & Events

Artelo Biosciences announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.20 per share, will be exercisable upon issuance and will expire five and one-half years from the Effectiveness Date. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $11M, prior to deducting placement agent fees and other offering expenses payable by the company. The company intends to use the net proceeds from the offering for working capital, general corporate purposes, and the repayment of certain bridge debt. The potential additional gross proceeds to the company from the warrants, if fully exercised on a cash basis, will be approximately $20.4M. No assurance can be given that any of the warrants will be exercised, or that the company will receive cash proceeds from the exercise of the warrants.

Artelo Biosciences announced a strategic expansion opportunity for ART27.13 in muscle preservation for patients undergoing glucagon-like peptide-1 receptor agonist therapy. The initiative is supported by four developments: observations of a muscle protective effect in the CAReS trial when ART27.13 was given to patients with cancer anorexia and cachexia and in preclinical research of cancer cachexia conducted at Trinity College Dublin, Ireland; publication of independent peer-reviewed research validating the differentiated pharmacology of ART27.13 compared to other CB2 agonists and supporting its potential utility in muscle preservation; filing of a provisional patent application covering the use of cannabinoid receptor agonism to prevent or mitigate muscle loss associated with GLP-1 therapy and initiation of a non-clinical study to evaluate ART27.13 in models relevant to GLP-1-associated muscle preservation. "GLP-1 medicines are reshaping the treatment landscape for obesity and metabolic disease, yet preservation of muscle and lean body mass remains a critical issue for patients, physicians, and the industry," said Andrew Yates, senior VP and chief scientific officer of Artelo. "We believe ART27.13 may represent a differentiated approach as a potential companion therapy in this setting. Based upon the results and analysis published in a recent independent research study, "Kinetic multiplex assay to assess biased signaling of clinical GPCR agonists", wherein the authors described ART27.13 as a superagonist, we consider our GPCR drug candidate to have one of the most compelling pharmacologic profiles among the 17 clinically studied CB2 agonists. With new non-clinical research commencing and the recent filing of a patent application covering the use of CB2 agonists with GLP-1 drugs, we are aiming to build a scientific and strategic foundation with ART27.13 in an area of potentially significant commercial relevance."

Artelo Biosciences files to sell 4.27M shares of common stock for holders

Artelo Biosciences files to sell 1.64M shares of common stock